Press release
Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD
New data shows long-term use of an AID system powered by Dexcom CGM can safely maintain improvements in glycaemic outcomes for up to two years1. Real-world
About this update from Dexcom, Inc.
[{"type":"text","content":"\n\nNew data shows long-term use of an AID system powered by Dexcom CGM can safely maintain improvements in glycaemic outcomes for up to two years1.\n\n\n\nReal-world evidence demonstrates reduction in severe hypoglycaemia and diabetic ketoacidosis over 12 months in people with Type 1 diabetes using a Dexcom-powered Automated Insulin Delivery (AID) system2.\n\n\n\nNew global user data analysis shows an association between Dexcom CGM usage and a meaningful reduction in HbA1c for people treating their T2D with a GLP-14.\n\n\n\nDexcom continues to enhance access to its portfolio around the world, including swift roll out of Dexcom ONE+ and the now, FDA cleared, Direct-to-Watch feature for G7.\n\n\n\n EDINBURGH, Scotland--(BUSINESS WIRE)--\nDexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical evidence supporting the use of Dexcom continuous glucose monitoring (CGM) for automated insulin delivery (AID) systems. Dexcom also announced data showcasing the significant benefits of CGM use for individuals managing Type 2 diabetes, along with groundbreaking evidence demonstrating a direct association between CGM use and reduced mortality in people with Type 1 and Type 2 diabetes. The evidence and data will be presented during Dexcom symposia and presentations at the 17th International Conference on Advanced Technologies and Treatments for Diabetes, held March 6-9, in Florence.\n\n\n“As the pioneer in biosensing, since last year’s ATTD, Dexcom has moved at an extraordinary pace. We launched G7 in 16 additional countries, released Dexcom ONE+ and are today announcing the phased launch of ‘Direct-to-watch’, that’s two best-in-class products and a feature designed to empower even more people living with diabetes. Globally, we’ve expanded access to Dexcom products by over 5 million people,” said Kevin Sayer, President, CEO, and Chairman of the Board at Dexcom.\n\n\nDriving access to best-in-class CGM technology\n\n\nDexcom has continued to drive access to its pioneering real-time CGM technology, launching its best-in-class G7 sensor in 16 new markets since ATTD 2023. The company’s latest sensor, Dexcom ONE+, which was built based on user and HCP feedback and is designed to be easy to use for anyone living with diabetes, has also launched in eig...